Why is healthcare AI stuck in pilot mode? UiPath has a straightforward answer

The gap between a successful AI pilot and a fully transformed healthcare operation is often wider than many organisations expect. UiPath bridges this gap by shifting the focus from simple automation to end-to-end orchestration

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uZbrVIa
via IFTTT

Read More

Roche brings 7-minute lung cancer shot to India

Roche Pharma India introduces a new injectable immunotherapy for lung cancer. This treatment takes only seven minutes, a significant reduction from hours-long infusions. It offers a less burdensome option for thousands of patients. The medicine, subcutaneous Tecentriq, is now approved for non-small cell lung cancer. This innovation aims to ease the strain on overcrowded cancer centers across India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/E0hqXGM
via IFTTT

Read More

Drug regulator drafts guidelines on high-risk solvents after tainted syrup deaths in kids

India's drug regulator is creating new rules for dangerous solvents in children's medicines. This follows tragic deaths linked to contaminated cough syrups. Experts found these solvents can contain toxic impurities. The regulator is consulting with companies to assess current practices and explore safer alternatives. This action is vital after several children died from Indian-made cough syrups.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OltYzga
via IFTTT

Read More

Zydus Lifesciences close to buying US oncology drug maker for $100 to 150 million: Sources

Indian drug maker Zydus Lifesciences is close to acquiring a US company. The deal is expected to be between $100 to $150 million. This acquisition will help Zydus build its own distribution network for anti-cancer drugs in the US. The target company also has its own pipeline of biologic drugs. A deal is anticipated soon.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2KAICpO
via IFTTT

Read More

Alzheimer's a key part of Eli Lilly's India specialty medicine push, says company's country head Winselow Tucker

Eli Lilly has introduced Lormalzi in India, a pioneering treatment for Alzheimer's that specifically targets amyloid plaques, a significant contributor to the condition. Unlike previous therapies that merely alleviate symptoms, this innovative medication aims to modify the disease itself.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/T78HK0t
via IFTTT

Read More

Hospitals warn Central Government Health Scheme reimbursement cap may hurt cancer treatment

A major private hospital group warns of a crisis for advanced cancer patients under the Central Government Health Scheme. A reimbursement cap on life-saving immunotherapy drugs is creating financial strain for hospitals. This policy threatens patient access to essential treatments. The association has identified nine specific drugs that are now out of reach for many beneficiaries.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4UdFNtG
via IFTTT

Read More

Eli Lilly halts India obesity awareness campaign after regulatory scrutiny, seeks rules clarity

Eli Lilly halted its obesity awareness campaign in India. The nation's drug regulator cautioned the company about potential violations. The campaign aimed to reframe obesity as a chronic disease. It featured various media without naming specific products. Lilly cited regulatory uncertainty and conflicting guidance. The regulator's advisory prohibited indirect promotion of medicines. This pause impacts a public health initiative.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oqNlEpf
via IFTTT

Read More